IL166625A0 - Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer - Google Patents

Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Info

Publication number
IL166625A0
IL166625A0 IL16662505A IL16662505A IL166625A0 IL 166625 A0 IL166625 A0 IL 166625A0 IL 16662505 A IL16662505 A IL 16662505A IL 16662505 A IL16662505 A IL 16662505A IL 166625 A0 IL166625 A0 IL 166625A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination
tyrosine kinase
kinase inhibitors
Prior art date
Application number
IL16662505A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166625A0 publication Critical patent/IL166625A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16662505A 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer IL166625A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218526.2A GB0218526D0 (en) 2002-08-09 2002-08-09 Combination therapy
PCT/GB2003/003390 WO2004014426A1 (fr) 2002-08-09 2003-08-05 Combinaison d'inhibiteurs du recepteur vegf de la tyrosine kinase utilisee pour le traitement du cancer

Publications (1)

Publication Number Publication Date
IL166625A0 true IL166625A0 (en) 2006-01-15

Family

ID=9942013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16662505A IL166625A0 (en) 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Country Status (14)

Country Link
US (2) US20050245549A1 (fr)
EP (1) EP1534338A1 (fr)
JP (1) JP2006500346A (fr)
KR (1) KR20050059060A (fr)
CN (1) CN100556456C (fr)
BR (1) BR0313117A (fr)
CA (1) CA2495489A1 (fr)
GB (1) GB0218526D0 (fr)
IL (1) IL166625A0 (fr)
MX (1) MXPA05001457A (fr)
NO (1) NO20050528L (fr)
NZ (1) NZ537754A (fr)
WO (1) WO2004014426A1 (fr)
ZA (1) ZA200501061B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
JP4593464B2 (ja) 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
ATE478671T1 (de) * 2003-07-10 2010-09-15 Astrazeneca Ab Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
JP2008514577A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ｚｄ６４７４及びイマチニブを含んでなる組合せ
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP2008536847A (ja) * 2005-04-14 2008-09-11 ワイス ゲフィニチブ耐性患者における上皮増殖因子レセプター（ｅｇｆｒ）キナーゼインヒビターの使用
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
EP1948179A1 (fr) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Derives de quinazoline pour le traitement des affections cancereuses
WO2007071958A2 (fr) * 2005-12-22 2007-06-28 Astrazeneca Ab Therapie combinee
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
WO2008034776A1 (fr) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Procédé de traitement du cancer présentant des mutations egfr
EP2066353B1 (fr) * 2006-09-29 2013-01-02 AstraZeneca AB Association de zd6474 et de bevacizumab pour traiter le cancer
WO2011003853A2 (fr) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Procédé de séchage du bibw2992, de ses sels et des préparations pharmaceutiques solides contenant ce principe actif
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002223684A1 (en) * 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
KR20040103964A (ko) * 2002-04-16 2004-12-09 아스트라제네카 아베 암 치료를 위한 조합 요법
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
CN1313094C (zh) * 2002-08-09 2007-05-02 阿斯利康(瑞典)有限公司 Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
ATE478671T1 (de) * 2003-07-10 2010-09-15 Astrazeneca Ab Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
JP2008514577A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ｚｄ６４７４及びイマチニブを含んでなる組合せ
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (fr) * 2005-12-22 2007-06-28 Astrazeneca Ab Therapie combinee

Also Published As

Publication number Publication date
NZ537754A (en) 2008-02-29
GB0218526D0 (en) 2002-09-18
ZA200501061B (en) 2007-01-31
US20050245549A1 (en) 2005-11-03
MXPA05001457A (es) 2005-06-06
BR0313117A (pt) 2005-07-05
EP1534338A1 (fr) 2005-06-01
WO2004014426A1 (fr) 2004-02-19
US20100130493A1 (en) 2010-05-27
CN1674938A (zh) 2005-09-28
CA2495489A1 (fr) 2004-02-19
AU2003252976A1 (en) 2004-02-25
JP2006500346A (ja) 2006-01-05
CN100556456C (zh) 2009-11-04
KR20050059060A (ko) 2005-06-17
NO20050528L (no) 2005-05-03

Similar Documents

Publication Publication Date Title
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
HUP0302544A3 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
HK1160859A1 (en) Inhibitors of tyrosine kinases
HK1085400A1 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
HK1086573A1 (en) Quinazoline derivatives for treatment of cancer
HK1092723A1 (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
HK1091480A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2003273842A8 (en) Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
IL183448A0 (en) Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
EP1651599A4 (fr) Inhibiteurs des tyrosine kinases
EP1496897A4 (fr) Inhibiteurs de tyrosines kinases
HK1120793A1 (en) 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
PL376255A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
EP1651209A4 (fr) Inhibiteurs de tyrosine kinase
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003219420A1 (en) Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera